The effect of body mass index (BMI) on outcomes after primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) is not well known. In patients registered in the Korean Acute Myocardial Infarction Registry (KAMIR) between November 2005 and November 2007, 3824 STEMI patients who arrived at hospital within 12 h after onset of chest pain and underwent primary PCI were analyzed, and divided into four groups according to their BMI: underweight (BMI < 18.5 kg/m 2 , n = 129); normal weight (18.5 ≤ BMI < 23.0 kg/m 2 , n = 1253); overweight (23.0 ≤ BMI < 27.5 kg/m 2 , n = 1959); and obese (BMI ≥ 27.5 kg/m 2 , n = 483). In-hospital mortality, revascularization in 1 year, mortality in 1 year, and overall mortality were compared between groups. Overweight and obese group were significantly younger, had normal left ventricular ejection fraction, and were more likely to be men with a higher incidence of hypertension, diabetes, and hyperlipidemia. There were no significant differences in symptom-to-door time and door-to-balloon time between groups. Obese patients had significantly lower in-hospital and overall mortalities. Major adverse cardiac events showed a bimodal pattern. Obese STEMI patients treated with primary PCI were associated with lower mortality, which may be explained by better use of medical treatment, hemodynamic stability, and younger age.
Introduction
Generally, overweight and obesity are associated with an increased risk of developing cardiovascular disease [1, 2] . Furthermore, obesity is associated with endothelial dysfunction, insulin resistance, and inflammation that may contribute to the increased risk for adverse cardiovascular clinical outcomes [3] . However, once coronary artery disease (CAD) developed in obese patients, poor clinical outcomes did not occur according to some reports [4] [5] [6] [7] [8] [9] .
Despite some data concerning the relationship between body mass index (BMI) and CAD existing, the clinical effect of BMI on outcomes after percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) is not well known. Furthermore, the available data are based on western populations, not on the oriental population.
Thus, we intended to evaluate the clinical effect of BMI on outcomes after PCI in Korean patients with STEMI using the Korean Acute Myocardial Infarction Registry (KAMIR).
Materials and methods

Study design and sample
KAMIR is a Korean prospective, open, observational, multicenter on-line registry investigating the risk factors of mortality in acute myocardial infarction (AMI) and establishing the universal management for the prevention of AMI with support of the Korean Circulation Society since November 2005. A total of 41 hospitals, which were capable of primary PCI, participated. This study evaluated age, sex, body mass index, initial symptoms, vital signs, Killip class, symptoms, onset time, ambulance arrival time, first medical contact time, transfer time from first hospital to the primary PCI centers, door to needle time, doorto-balloon time, each risk factor, past regular medication, co-morbidities, electrocardiographic locations of MI, initial treatment strategy, drugs, angiographic findings, in-hospital complications, medical therapy in hospital, 1-, 6-, and 12-month follow-up major adverse cardiac events (MACEs) (cardiac death, re-infarction, re-PCI, coronary artery bypass graft), and so on. We used KAMIR to define a cohort of patients with AMI. The study protocol was approved by the ethics committee at each participating institution. The diagnosis of AMI was based on the triad of chest pain, ECG changes, and raised serum cardiac enzyme level. During our study period of November 2005 to November 2007, 3824 STEMI patients who arrived at hospital within 12 h after onset of chest pain and underwent primary PCI were registered in KAMIR. For this analysis, patients were classified into four groups based on the suggestion by the World Health Organization for the Asian population [10] : underweight (Group I: BMI < 18.5 kg/m 2 , n = 129); normal weight (Group II: 18.5 ≤ BMI < 23.0 kg/m 2 , n = 1253); overweight (Group III: 23.0 ≤ BMI < 27.5 kg/m 2 , n = 1959); and obese (Group IV: BMI ≥ 27.5 kg/m 2 , n = 483). Patients' characteristics consisted of medical history (diabetes mellitus, hypertension, smoking, hyperlipidemia, previous AMI, previous angina, previous coronary artery bypass graft, previous PCI, and family history); presentation characteristics (systolic blood pressure and heart rate, symptom-to-door time, door-to-balloon time, and left ventricular ejection fraction, which was obtained within 24 h after admission in most cases); the laboratory findings (glucose, creatinine, cardiac enzymes, serum cholesterol, high-sensitivity C-reactive protein, and N-terminal pro-brain natriuretic peptide); and the medical treatment; and angiographic and procedural findings. In-hospital mortality, MACEs, including in-hospital mortality, revascularization, mortality in 1, 6, 12 months, and overall mortality were compared among the four groups.
Statistical analysis
Statistical analysis was performed using SPSS software, version 15.0 (SPSS-PC Inc., Chicago, IL, USA). All continuous variables are reported as mean value ± standard deviation (SD). We used Chi-square tests for linear-by-linear association, or one-way ANOVA for statistical comparisons of clinical characteristics among groups. Survival analysis after AMI was estimated using the Kaplan-Meier method with logrank tests to compare survival among groups. Univariate and multivariate analysis were done to identify the prognostic factors affecting results. We used Chi-square tests and independent-samples t-tests to find the predictors for overall mortality and used logistic regression analysis to adjust confounding factors. A p-value < 0.05 was considered as significant.
Results
Baseline characteristics
Baseline characteristics of the patient groups are listed in Table 1 . Overweight and obese group were significantly younger (Group I: 69.7 ± 12.7 years, II: 64.7 ± 12.2 years, III: 59.4 ± 11.9 years, and IV: 56.5 ± 12.5 years, p < 0.001) and more likely to be male patients (Group I: 62.8%, II: 70.9%, III: 79.5%, and IV: 76.4%, p = 0.009) with higher incidences of hypertension (Group I: 33.3%, II: 39.9%, III: 47.2%, and IV: 54.2%, p < 0.001), diabetes (Group I: 17.3%, II: 22.5%, III: 23.5%, and IV: 28.7%, p = 0.005), smoking (Group I: 58.9%, II: 60.3%, III: 64.2%, and IV: 66.2%, p = 0.006), and hyperlipidemia (Group I: 9.8%, II: 7.0%, III: 10.4%, and IV: 12.7%, p = 0.001). There were no significant statistical differences in symptom-to-door time and doorto-balloon time (p > 0.05). Underweight patients had lower left ventricular ejection fraction (Group I: 48.3 ± 14.0%, II: 50.3 ± 11.7%, III: 51.3 ± 11.3%, and IV: 52.6 ± 11.6%, p < 0.001), lower systolic (Group I: 117.9 ± 33.6 mmHg, II: 122.6 ± 38.7 mmHg, III: 125.8 ± 30.1 mmHg, and IV:
129.1 ± 30.8 mmHg, p < 0.001) and diastolic blood pressure (Group I: 71.7 ± 19.8 mmHg, II: 75.7 ± 31.9 mmHg, III: 78.7 ± 24.8 mmHg, and IV: 80.6 ± 18.3 mmHg, p < 0.001) and higher rate of Killip class 1 (Group I: 28.7%, II: 25.4%, III: 22.4%, and IV: 22.5%, p = 0.001) ( Table 1) . Table 2 shows results of the laboratory examination. Overweight and obese patients had higher levels of total cholesterol (Group I: 163.9 ± 50.2 mg/dL, II: 175.4 ± 42.8 mg/dL, III: 185.3 ± 42.7 mg/dL, and IV: 191.7 ± 44.6 mg/dL, p < 0.001) and low-density lipoprotein cholesterol (Group I: 101.9 ± 42.5 mg/dL, II: 111.3 ± 36.6 mg/dL, III: 120.4 ± 44.7 mg/dL, and IV: 124.2 ± 53.1 mg/dL, p < 0.001). N-terminal pro-brain natriuretic peptide became significantly lower, as BMI increased (Group I: 3991.1 ± 7436.2 pg/mL, II: 1863.3 ± 4854.7 pg/mL, III: 1194.5 ± 3661.2 pg/mL, and IV: 845.9 ± 2901.5 pg/mL, p < 0.001). Also, there were no clinical differences in the levels of glucose, creatinine, and high-sensitivity C-reactive protein between groups.
Laboratory findings
Medical treatment parameters
At admission, we used ␤-blockers (Group I: 57.0%, II: 72.0%, III: 75.4%, and IV: 78.9%, p < 0.001) and statins (Group I: , p = 0.005) were prescribed more frequently in the underweight group. Except for those medications, there were no significant differences between groups in the usage of other medications (Table 3) .
Coronary angiogram and PCI
In underweight group, there was a higher incidence of left main complex lesion (Group I: 2.4%, II: 1.8%, III: 1.5%, and IV: 0.2%, p = 0.017) and left anterior descending coronary artery for the target vessel (Group I: 54.0%, II: 50.4%, III: 49.5%, and IV: 43.5%, p = 0.015). The higher BMI, the bigger stent (Group I: 3.11 ± 0.4 mm, II: 3.18 ± 0.4 mm, III: 3.24 ± 0.4 mm, and IV: 3.28 ± 0.5 mm, p < 0.001) was used and the lower events of complication (Group I: 26.8%, II: 18.0%, III: 16.2%, and IV: 15.3%, p = 0.007) occurred. Despite the use of drug-eluting stents in most cases, there was a trend to use bare metal stents in the underweight group (Table 4 ). 
Major adverse cardiac events and all-cause mortality
Survival curves and multivariate analysis for overall mortality
Kaplan-Meier survival curves for mortality showed significantly higher mortality in underweight patients (Fig. 1 ). In the multivariate regression analysis, we found that no use of statins, old age, higher Killip class, and lower left ventricu- lar ejection fraction were independent predictors of overall mortality ( Table 6 ).
Discussion
Our data revealed that overweight and obese patients had worse baseline characteristics, including hypertension, diabetes, smoking, and hyperlipidemia. Conversely, underweight patients had poor profiles associated with hemodynamic instability, including older age, lower blood pressure, higher Killip class, and lower left ventricular ejection fraction. Our clinical follow-up results showed that obese and overweight patients had better short-and longterm prognosis than underweight patients. Not only are overweight and obesity associated with increased risk of developing cardiovascular disease [1, 2] , but also obesity is associated with endothelial dysfunction, insulin resistance, and inflammation that may contribute to an increased risk for adverse clinical outcomes [3] . So, we initially hypothesized that the obese and overweight patients who received primary PCI in STEMI would have poor prognosis compared with counterparts, despite some data supporting the obesity paradox in coronary artery disease [4] [5] [6] [7] [8] [9] .
What made these results? Our analysis showed that increased body mass index is associated with greater use of guideline-recommended therapies on admission. ␤-Blockers, angiotensin-converting enzyme inhibitors, and statins were prescribed more frequently for overweight and obese patients. As shown in Table 6 , statins provide an independent protective effect in overall mortality. This trend was consistent with a previous report advocated by Steinberg et al. [11] . They concluded that overweight and obese patients with acute myocardial infarction or unstable angina were more likely to receive aspirin, ␤-blockers, inhibitors of the rennin-angiotensin system, and lipid-lowering agents, and that they also were more likely to undergo cardiac catheterization, PCI, and coronary artery bypass graft. Because obese and overweight patients have more traditional risk factors for CAD and are expected to better tolerate aggressive management, medical teams give more guideline-recommended therapies on admission [12] [13] [14] [15] . As proven in previous studies, there is a link between invasive management of acute coronary syndrome and use of proved, evidence-based treatments [16, 17] . This is why we first thought that the most important reason why overweight and obese patients with STEMI undergoing PCI had good outcomes.
In addition, overweight and obese patients had higher blood pressure, lower Killip class, and higher left ventricular ejection fraction compared with underweight patients, indicating they were relatively in a more hemodynamically stable state. Our multivariate analysis showed hemodynamic instability, including lower left ventricular ejection fraction and higher Killip class are independent predictors of overall mortality. Underweight patients, in whom there was hemodynamic instability, had a trend of less frequent use of ␤-blockers and angiotensin-converting enzyme inhibitors, and more frequent use of vasopressors and diuretics. Also, we could find the hemodynamic state in laboratory findings. Serum N-terminal pro-brain natriuretic peptide level was significantly lower in overweight and obese patients. The level of N-terminal pro-brain natriuretic peptide, an indicator of the hemodynamic severity of MI and left ventricular dysfunction, is considered one of the most powerful predictors of death in AMI [18] [19] [20] . Therefore, overweight and obese patients who were in a hemodynamically stable state compared with underweight and normal weight patients may have favorable outcomes according to the present study.
In the present study, elderly patients were more frequently in the underweight and normal weight groups. Previous reports revealed that elderly patients had worse outcomes after AMI regardless of treatment [21, 22] . Our multivariate analysis demonstrated that age is an independent risk factor for overall mortality. This result was consistent with previous studies. Physicians had a tendency of more aggressive use of medications for younger patients that may influence a favorable effect on outcomes [23] . Recent studies demonstrated that younger age in obesity had a major impact on protection in AMI [24, 25] .
Study limitations
Although BMI has been considered as a marker of obesity, it is a crude indicator of body adiposity, not a direct measurement of body composition. So, it may not reflect the actual degree of body fat content. We did not define obesity by other methods such as waist circumference, waist-hip ratio, or abdominal height. Also, we did not have the data related to the change in BMI or weight during the follow-up period. Therefore, we could not determine the impact of weight reduction on outcomes after primary PCI, especially in overweight or obese patients.
KAMIR is an observational registry rather than a randomized trial. Therefore, our analysis has all the limitations of retrospective analysis using prospectively collected data. Also, the follow-up duration was relatively short. Therefore we could not exclude the possibility that obesity may influence the very long-term outcomes, because obesity may have a delayed effect on the progression of coronary artery disease.
Conclusion
Obesity is not an independent predictor of overall mortality in patients with STEMI undergoing primary PCI. However, obese patients are associated with lower mortality. These results can be explained by better use of guideline-recommended medical treatment, hemodynamic stability, and younger age. To identify the impact of obesity on outcomes in patients undergoing primary PCI and to elucidate the long-term effect, a well-designed prospective study may be needed. Jae Joo, MD; Soo Joong Kim, MD; Dong Kyu Jin, MD; Jin Man Cho, MD; Wook Sung Chung, MD; Yang Soo Jang, MD; Jeong Gwan Cho, MD; Ki Bae Seung, MD; Seung Jung Park, MD.
